Patents by Inventor Xingyue He

Xingyue He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20240050473
    Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) and chimeric antigen receptors comprising GCC antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules are provided herein.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Inventors: Gary SHAPIRO, Johara CHOUITAR, Xingyue HE, Mei Rosa NG
  • COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20240033359
    Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules provided herein.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 1, 2024
    Inventors: Gary SHAPIRO, Xingyue HE, Mei Rosa NG, Lorraine THOMPSON, Elena DE JUAN FRANCO, Steven VANCE
  • CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND USE THEREOF
    Publication number: 20230346938
    Abstract: The presently disclosed subject matter provides chimeric antigen receptors (CARs) that specifically target CD19 and cells comprising such CD19-targeted CARs. The presently disclosed subject matter further provides uses of the CD19-targeted CARs for treatment, e.g., for treating blood cancer.
    Type: Application
    Filed: October 24, 2022
    Publication date: November 2, 2023
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORAIL HOSPITAL FOR CANCER AND ALLIED DISEASES, MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Judith FEUCHT, Jorge MANSILLA-SOTO, Isabelle RIVIERE, Michel SADELAIN, Loic VINCENT, Gary SHAPIRO, Mei Rosa NG, Dan TAVARES, Xingyue HE
  • ANTI-ADGRE2 ANTIBODIES AND USES THEREOF
    Publication number: 20230018888
    Abstract: Antibodies, fragments thereof and fusion proteins that specifically bind to ADGRE2, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various autoimmune diseases and cancers, including, for example, acute myeloid leukemia.
    Type: Application
    Filed: April 25, 2022
    Publication date: January 19, 2023
    Inventors: Antara Banerjee, Xingyue He, Shawn Jennings
  • CHIMERIC RECEPTORS TARGETING ADGRE2 AND/OR CLEC12A AND USES THEREOF
    Publication number: 20220363775
    Abstract: The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 17, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, MILLENNIUM PHARMACEUTICALS, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Michel Sadelain, Sascha P. Haubner, Jorge Mansilla-Soto, Xingyue He, Gary Shapiro
  • Compositions and methods for generating induced pluripotent stem cells
    Patent number: 9132152
    Abstract: The present disclosure provides a method of generating an induced pluripotent stem cell; as well as nucleic acids and genetically modified host cells useful in generating iPSCs. The present disclosure provides iPSCs, and methods of use of same.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: September 15, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Lin He, Yong Jin Choi, Chao-Po Lin, Gregory J. Hannon, Xingyue He
  • Methods of using MIR34 as a biomarker for TP53 functional status
    Patent number: 8399248
    Abstract: In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: March 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michele A. Cleary, Aimee L. Jackson, Peter S. Linsley, Julja Burchard, Lee P. Lim, Jill F. Magnus, Lin He, Xingyue He, Scott W. Lowe, Gregory J. Hannon
  • COMPOSITIONS AND METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS
    Publication number: 20120207723
    Abstract: The present disclosure provides a method of generating an induced pluripotent stem cell; as well as nucleic acids and genetically modified host cells useful in generating iPSCs. The present disclosure provides iPSCs, and methods of use of same.
    Type: Application
    Filed: February 9, 2012
    Publication date: August 16, 2012
    Inventors: Lin He, Yong Jin Choi, Chao-Po Lin, Gregory J. Hannon, Xingyue He
  • METHODS OF USING MIR34 AS A BIOMARKER FOR TP53 FUNCTIONAL STATUS
    Publication number: 20110105583
    Abstract: In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.
    Type: Application
    Filed: May 5, 2008
    Publication date: May 5, 2011
    Applicants: MERCK & CO., INC., COLD SPRING HARBOR LABORATORY
    Inventors: Michele A. Cleary, Aimee L. Jackson, Peter S. Linsley, Julja Burchard, Lee P. Lim, Jill F. Magnus, Lin He, Xingyue He, Scott W. Lowe, Gregory J. Hannon